Literature DB >> 16481629

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

S P L Travis1, E F Stange, M Lémann, T Oresland, Y Chowers, A Forbes, G D'Haens, G Kitis, A Cortot, C Prantera, P Marteau, J-F Colombel, P Gionchetti, Y Bouhnik, E Tiret, J Kroesen, M Starlinger, N J Mortensen.   

Abstract

This second section of the European Crohn's and Colitis Organisation (ECCO) Consensus on the management of Crohn's disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn's disease. The third section on special situations in Crohn's disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn's disease.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16481629      PMCID： PMC1859997          DOI： 10.1136/gut.2005.081950b

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  195 in total

1.  The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.

Authors:  L Marchal; G D'Haens; G Van Assche; S Vermeire; M Noman; M Ferrante; M Hiele; M Bueno De Mesquita; A D'Hoore; F Penninckx; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171

2.  Proctocolectomy is associated with a higher complication rate but carries a lower recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis.

Authors:  T Yamamoto; M R Keighley
Journal:  Scand J Gastroenterol       Date:  1999-12       Impact factor: 2.423

3.  Treatment of Crohn's colitis. Segmental or total colectomy?

Authors:  W E Longo; G H Ballantyne; C E Cahow
Journal:  Arch Surg       Date:  1988-05

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Authors:  R Löfberg; P Rutgeerts; H Malchow; C Lamers; A Danielsson; G Olaison; D Jewell; O Ostergaard Thomsen; H Lorenz-Meyer; H Goebell; H Hodgson; T Persson; C Seidegård
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

6.  The influence of disease at the margin of resection on the outcome of Crohn's disease.

Authors:  R Heuman; B Boeryd; T Bolin; R Sjödahl
Journal:  Br J Surg       Date:  1983-09       Impact factor: 6.939

7.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

9.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.

Authors:  T Ljung; P Karlén; D Schmidt; P M Hellström; A Lapidus; I Janczewska; U Sjöqvist; R Löfberg
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

10.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245
View more
  137 in total

1.  Framework for assessing quality of care for inflammatory bowel disease in Sweden.

Authors:  Martin Rejler; Jörgen Tholstrup; Mattias Elg; Anna Spångéus; Boel Andersson Gäre
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

2.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

3.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

4.  MR motility imaging in Crohn's disease improves lesion detection compared with standard MR imaging.

Authors:  Johannes M Froehlich; Christian Waldherr; Christoforos Stoupis; S Mehmet Erturk; Michael A Patak
Journal:  Eur Radiol       Date:  2010-04-09       Impact factor: 5.315

5.  Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet.

Authors:  Mitsuro Chiba; Toru Abe; Hidehiko Tsuda; Takeshi Sugawara; Satoko Tsuda; Haruhiko Tozawa; Katsuhiko Fujiwara; Hideo Imai
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

6.  Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes.

Authors:  Stephen B Hanauer; Daniel H Present; David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2009-06

Review 7.  Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease--review of the literature.

Authors:  Andreas G Wibmer; Anton J Kroesen; Jörn Gröne; Heinz-Johannes Buhr; Joerg-Peter Ritz
Journal:  Int J Colorectal Dis       Date:  2010-07-14       Impact factor: 2.571

8.  Immunomodulators for all patients with inflammatory bowel disease?

Authors:  Sandro Ardizzone; Andrea Cassinotti; Gianpiero Manes; Gabriele Bianchi Porro
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

9.  Optimal use of biologics in the management of Crohn's disease.

Authors:  Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

10.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.